Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma

BACKGROUND: A high-quality programmed cell-death ligand 1 (PD-L1) diagnostic assay may help predict which patients are more likely to respond to anti-programmed cell death-1 (PD-1)/PD-L1 antibody-based cancer therapy. Here we describe a PD-L1 immunohistochemical (IHC) staining protocol developed by...

Descripción completa

Detalles Bibliográficos
Autores principales: Rebelatto, Marlon C., Midha, Anita, Mistry, Amita, Sabalos, Constantine, Schechter, Nicole, Li, Xia, Jin, Xiaoping, Steele, Keith E., Robbins, Paul B., Blake-Haskins, John A., Walker, Jill
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055695/
https://www.ncbi.nlm.nih.gov/pubmed/27717372
http://dx.doi.org/10.1186/s13000-016-0545-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055695/
https://www.ncbi.nlm.nih.gov/pubmed/27717372
http://dx.doi.org/10.1186/s13000-016-0545-8

Ejemplares similares